Pulse Biosciences, Inc. (NASDAQ:PLSE) Files An 8-K Other EventsITEM 8.01. OTHER EVENTS
On September 11, 2017, Pulse Biosciences, Inc. issued a press release announcing that, on September 8, 2017, Pulse Biosciences Inc. withdrewits 510(k) Application for the PulseTx™Nano-Pulse Stimulation System and plans to submit the supplemental information in a subsequent510(k) application in the coming months.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
(d) |
Exhibits. |
|
Exhibit No. |
Description |
|
99.1 |
Press Release issued by Pulse Biosciences, Inc. dated September 11, 2017. |
Pulse Biosciences, Inc. ExhibitEX-99.1 2 plse-20170911xex99_1.htm EX-99.1 Exhibit 991 Exhibit 99.1 PULSE BIOSCIENCES ANNOUNCES WITHDRAWAL AND PLANNED RESUBMISSION OF 510(k) APPLICATION FOR THE PULSETXTM SYSTEM HAYWARD,…To view the full exhibit click here
About Pulse Biosciences, Inc. (NASDAQ:PLSE)
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.